DCM
DFTX

Driehaus Capital Management’s Definium Therapeutics DFTX Stock Holding History

Driehaus Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322M Buy
6,845,276
+933,387
+16% +$23.1M 1.87% 2
2026
Q1 		$112M Sell
5,911,889
-625,313
-10% -$10.6M 0.82% 21
2025
Q4 		$87.5M Buy
6,537,202
+3,427,291
+110% +$42.4M 0.59% 43
2025
Q3 		$36.7M Buy
3,109,911
+17,253
+0.6% +$161K 0.26% 128
2025
Q2 		$20.1M Sell
3,092,658
-258,747
-8% -$1.7M 0.16% 176
2025
Q1 		$19.6M Sell
3,351,405
-24,802
-0.7% -$178K 0.19% 164
2024
Q4 		$23.5M Sell
3,376,207
-517,920
-13% -$3.56M 0.19% 158
2024
Q3 		$22.2M Buy
3,894,127
+1,355,717
+53% +$9.43M 0.19% 158
2024
Q2 		$18.3M Sell
2,538,410
-9,135
-0.4% -$79.9K 0.18% 162
2024
Q1 		$23.9M Buy
+2,547,545
New +$14.5M 0.24% 123

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Driehaus Capital Management's DFTX Position: Q2 2026 in Review

Driehaus Capital Management increased its Definium Therapeutics (DFTX) stake by 16% in Q2 2026, buying an estimated $23.1M and bringing the position to 6,845,276 shares worth $322M. The position accounts for 1.87% of the portfolio, ranked #2.

Driehaus Capital Management first reported a position in DFTX in Q1 2024 and has held it in 10 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Driehaus Capital Management held 6,845,276 shares of Definium Therapeutics worth $322M as of Q2 2026.
  • Driehaus Capital Management bought 933,387 Definium Therapeutics shares in Q2 2026, an estimated $23.1M.
  • Definium Therapeutics made up 1.87% of Driehaus Capital Management's portfolio in Q2 2026, its #2 holding.
  • Driehaus Capital Management first reported a position in Definium Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.